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OBJECTIVE — To assess associations between peripheral sensory neuropathy (PSN) and
other diabetes-related complications.
RESEARCH DESIGN AND METHOD — In an area-based cohort of type 2 diabetic
subjects, we investigated 156 subjects (age 61.7  7.2 years and diabetes duration 7.0  5.7
years)byquestionnaires,clinicalexaminations,bloodandurinesampling,andreviewofmedical
records.
RESULTS — Prevalence of PSN, assessed by monoﬁlament and neurothesiometer testing,
increased with severity of retinopathy (50% frequency in moderate and 100% in severe or
proliferative retinopathy; P  0.02). Vibration perception threshold was higher in subjects with
retinopathy (25.6  8.9 vs. 20.5  8.9 V; P  0.007). PSN was more common in subjects with
overt nephropathy, with higher vibration perception thresholds, than in subjects without overt
nephropathy. Subjects with PSN but no retinopathy had twice the prevalence of peripheral
vascular disease (PVD) (52%) as subjects with both PSN and retinopathy (19%; P  0.05). In
subjects with PSN alone, PVD was three times more likely (52%) than in subjects without PSN
(16%; P  0.001). In multivariate analysis, PSN was independently associated with PVD (odds
ratio 2.31; P  0.007), age (1.12; P  0.008), male sex (2.01; P  0.02), and HDL cholesterol
(0.21; P  0.05) and tended to be independently associated with IGF-1 binding protein (1.03;
P  0.05) but not with diabetes duration or A1C.
CONCLUSIONS — In a representative population of type 2 diabetes, PSN is related to
microvascular and macrovascular pathology. PSN is possibly affected by the IGF axis.
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P
eripheral sensory neuropathy (PSN)
is a well-known complication of di-
abetes attributed to chronic hyper-
glycemia (1,2). However, the risk of PSN
is also increased by advancing age and af-
fected by height and possibly by sex (3)
and poorly deﬁned factors, such as pro-
cesses coupled to regulation of IGF-1
(4,5). This makes it difﬁcult to identify
speciﬁc diabetes components of neurop-
athy. Retinopathy, on the other hand, is a
complication of diabetes strictly coupled
to metabolic control and is also more eas-
ily investigated (1). It could be conjec-
tured that metabolic control would be a
strong determinant of PSN in subjects
with both retinopathy and neuropathy
but less so in diabetic subjects with neu-
ropathy alone. It follows that other risk
factors for neuropathy would be impor-
tant in the latter subjects. However, this
concept has, to our knowledge, not been
fully investigated in a representative pop-
ulation of type 2 diabetic patients.
To analyze PSN in relation to other
complications and disease conditions, we
investigatedtheprevalenceofclinicaland
biochemical signs of vascular and neuro-
logical dysfunction during foot examina-
tions of type 2 diabetic patients from a
population near Sundbyberg, a suburb of
Stockholm. A standardized foot examina-
tion protocol based on international con-
sensus statements, which have been in
use since 1993, was used. Further, we ex-
amined and recoded all retinal records
available, thus enabling a comparison of
neuropathic subjects with and without
concurrent retinopathy. Lastly, we tested
for associations between PSN and abnor-
malities of the IGF-1 and its binding
proteins.
RESEARCH DESIGN AND
METHODS— Subjects from the ur-
ban area of Sundbyberg, a suburb of
Stockholm, were asked to participate. In
the area where the study was performed,
89% of the population had their health
care served by three primary health care
centers. Men and women, 40–70 years of
age, diagnosed with type 2 diabetes after
the age of 35 were included. Latent auto-
immune diabetes in adults (LADA) sub-
jects were excluded based on assays of
GAD antibodies. The study was approved
by the local ethics committee at the Karo-
linska University Hospital. All partici-
pants gave informed consent.
Experimental protocol: data
assembled on examination day
Patients were examined at the Unit for
Metabolic Control or the Clinical Re-
search Centre at Karolinska University
Hospital after an overnight fast. No
medicationwastakenonthemorningof
admission. Patients who were treated
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ter 2200 h on the day preceding the
examination.
Before their visit, the patients had re-
ceived questionnaires concerning their
social situation, diabetes, and relevant
medical data. The resulting medical his-
tory was later veriﬁed by review of medi-
cal records. Height and weight were
measured with the subject wearing light
indoor clothing without shoes. Waist in-
dexwascalculatedaswaistcircumference
(cm) divided by 94 for men and 80 for
women (the limits for overweight). Blood
pressure was measured in the supine po-
sition after 5 min of rest. An electrocar-
diogram was registered after another 15
min. A urine sample was secured on the
night preceding the examination. Blood
samples were taken in the overnight fast-
ing state between 0900 and 1000 h. Sam-
ples, except those analyzed by routine,
were processed immediately, aliquoted
into 0.5 ml microtubes, and frozen at
70°C until assay.
Foot examination
Vibrationperceptionthreshold(VPT)was
assessed at the metatarsophalangeal joint
dig I using a neurothesiometer (Horwell,
NEU1501, U.K.) in a two-step manner
starting from 50 V with decreasing stim-
ulation and then starting from 0 V with
increasing stimulation. The subjects (n 
150) stated when they began to feel or
stopped feeling vibration. The mean of
the two measurements for the least sen-
sitive foot was used in further analyses
(2). Sensitivity to touch was tested us-
ing a monoﬁlament (10 g Touch Test
5.07;NovoNordisk,Copenhagen,Den-
mark) at four points on each foot: three
on the plantar and one on the dorsal
side. The procedure was repeated once.
Three mistakes out of four were consid-
ered pathological (2). Peripheral sen-
sory neuropathy was deﬁned as VPT
25 V or inability to feel the monoﬁla-
ment. Foot pulses (dorsalis pedis and
tibialis posterior arteries) were pal-
pated. Both pulses were required to be
palpable for a normal macrocirculation.
Assessment of retinopathy
Records were available for most of the
study patients in terms of retinal photog-
raphy (n  111) and ophthalmoscopy
(n  21). The photographic records were
reviewed and the severity of retinopathy
assessed by an experienced retina oph-
thalmologist (G.v.W.). Assessment of ret-
inopathy was based on the most afﬂicted
eye or on one eye only when the photo-
graphs of only one eye were assessable or
available. The condition of retinopathy was
classiﬁed into ﬁve categories using an
international system of classiﬁcation
(6): absence of retinopathy, mild non-
proliferative retinopathy, moderate
nonproliferative retinopathy, severe
nonproliferative retinopathy, and pro-
liferative retinopathy. Subjects for
whom records of such investigations
were lacking were excluded from the
retinopathy part of the study.
Other classiﬁcations and deﬁnitions
Cardiovascular disease (CVD) was de-
ﬁnedasahistoryofmyocardialinfarction,
angina pectoris or ischemic heart disease,
ongoing treatment with drugs prescribed
forCVD,orthepresenceofapathological
electrocardiogram according to the Min-
nesotacode.Acerebrovascularlesionwas
considered present if diagnosed accord-
ing to medical records or if a pathological
ﬁnding by computed tomography of the
brain had been registered.
Peripheralvasculardisease(PVD)was
deﬁned as clinical macroangiopathy (no
pulses) present during a foot examination
or a medical history of symptoms typical
of intermittent claudication. Overt ne-
phropathy was deﬁned as albuminuria
300 mg/l or serum creatinine 100
mol/l for women and 110 mol/l for
men. Incipient nephropathy was deﬁned
as albuminuria 30–299 mg/l. Hyperten-
sion was deﬁned as 140/90 mmHg at
examination or presence of antihyperten-
sive treatment.
Hyperlipidemia was considered
present when lipid-lowering drugs were
in use or when samples at admission
showed total cholesterol 5 mmol/l or
triglycerides 1.7 mmol/l. (In Sweden,
lipid-lowering drugs are prescribed to
achieve total cholesterol 4.5 mmol/l
and LDL cholesterol 2.6 mmol/l.)
LADA was deﬁned by the presence of
GAD antibodies 9.5 units/l. GAD anti-
body titers were determined with diamyd
anti-GAD65 radioimmunoassay (RIA)
(Diamyd Diagnostics AB, Stockholm,
Sweden) (7,8).
Assays
IGF-1 (g/l) was determined by RIA after
separation from IGF-binding proteins
(IGFBPs) by acid-ethanol extraction and
cryoprecipitation. To minimize the inter-
ference of the remaining IGFBPs,
des(1–3) IGF-1 was used as the radioli-
gand.Theintra-assayandinterassaycoef-
ﬁcients of variation (CVs) were 4 and
11%, respectively.
IGFBP-1 (g/l) was determined by
RIA according to the method of Po ´voa et.
al (9). The sensitivity of the RIA was 3
g/l, and the intra- and interassay CVs
were 3 and 10%, respectively.
IGFBP-3 (g/l) was determined
with a solid-phase, enzyme-labeled
chemiluminescent immunometric assay
(Immulite 2000 IGFB-3; DPC, Los An-
geles, CA). According to the manufac-
turer, the assay is highly speciﬁc with
low cross-reactivity, and analytical sen-
sitivityis100g/l.Intra-andtotalassay
CVs were 4.2 and 7.2%, respectively.
High-sensitive C-reactive protein
(hsCRP) was determined with immunon-
ephelometry (OQIY N High-sensitive
CRP; Dade Behring, Schwalbach, Ger-
many). The expected normal value of
hsCRP is 2 mg/l.
Lipoproteins were processed with
12-hpreparativeultracentrifugation,after
which the VLDL cholesterol fraction was
separated and analyzed. After precipita-
tion of LDL cholesterol, HDL cholesterol
was separated and analyzed. LDL choles-
terol was calculated according to the
Friedewald formula. Cholesterol and tri-
glyceride levels were determined after ex-
traction with dichloromethane and
methanol.
Cystatin C was determined with N
Latex Cystatin C (OQNM; Dade Behring,
Schwalbach, Germany). The normal in-
terval of cystatin C is 0.53–0.95 mg/l.
A1C (ref. 5.2%) was determined
with the immunological Mono-S method
using Unimate (Roche Diagnostics, Indi-
anapolis,IN).Fastingplasmaglucose(ref.
4.0–6.0mmol/l),S-creatinine(ref.100
mol/l for women and 110 mol/l for
men), and urinary albumin (ref. 30
mg/l) were analyzed by routine methods
at the hospital laboratory.
Statistical analysis
All results are expressed as mean SD,
unless otherwise stated. Parameters with
nonnormal distributions were trans-
formed, and log-normalized values were
used for signiﬁcance testing. If log-
normalization was not acceptable, the
Mann-Whitney U test or Kruskal-Wallis
ANOVA was used. Levels of signiﬁcance
were tested with Fisher’s exact two-tailed
test for simple frequency when n 10;
otherwise Pearson’s 
2 test was used. Stu-
dent’s t test and one-way ANOVA were
used for parametric variables classiﬁed in
two groups or more. Logistic regressions
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dent variables and factors of signiﬁcance
previouslyreportedtostudyindependent
associations.
RESULTS— The prevalence of type 2
diabetes among those 40–70 years of age
was 3.5% in the area that we studied (in-
cluding participants and nonpartici-
pants). The participation rate was 68%.
Participants and nonparticipants
were comparable as to sex, age, diabetes
duration, antidiabetes treatments, glu-
cose control, and diabetes complications.
However,accordingtothereviewofmed-
ical records, more nonparticipating dia-
betic patients had a diagnosis of CVD and
hypertension than participants (CVD 31
vs. 16%, P  0.05; and hypertension 47
vs. 30%, P  0.06, respectively). Hence,
the study population had somewhat
fewer macrovascular complications.
The study population was 95% Cau-
casian, 61% male, and 39% female.
MeanSDagewas61.77.2yearswith
diabetes duration 7.0  5.7 years, BMI
29.2  4.8 kg/m
2, and A1C 6.4  1.3%.
Therewasnocorrelationbetweenageand
diabetes duration or differences in rela-
tiontosex(datanotshown).Antidiabetes
treatments consisted of diet alone (28%),
antidiabetes agent (44%), insulin (19%),
and a combination of antidiabetes agent
and insulin (8%). Metformin was used by
21% of the study population and sulfo-
nylurea drugs by 44%. At examination,
63% of the subjects were hypertensive
and 51% received antihypertensive treat-
ment.Hyperlipidemiaaffected69%ofthe
population, treated and untreated.
Women were affected more frequently
than men (87 vs. 59%; P  0.0002).
Twenty-six percent of the whole popula-
tion received treatment with lipid-
lowering agents (statins 20% and ﬁbrates
8%). Thirty-one percent were present
smokers, and 33% were former smokers,
with men more often former smokers. Six
percent had experienced some problem
with alcohol overconsumption according
tomedicalrecords.Theprevalenceofma-
crovascular complications was 62% for
CVD,26%forPVD,and11%forcerebro-
vascular lesions, with no difference be-
tween men and women.
Neuropathy, univariate correlations
PSN affected 34% of the subjects. Men
weremoreoftenaffectedthanwomen(43
vs. 20%; P  0.006) (Table 1 and online
appendix Table A1 [available at http://dx.
doi.org/10.2337/dc08-1250]). Subjects
with PSN were older than those without
PSN(64.75.2vs.59.77.6years;P
0.006) and had longer diabetes duration
(8.6  6.3 vs. 6.1  4.9 years; P  0.01).
They were more affected by nephropathy
as judged by higher cystatin C (0.88 
0.42 vs. 0.71  0.29 mg/l; P  0.02) and
higher albuminuria (172  483 vs. 31 
119 mg/l; P  0.007). The prevalence of
PSN increased with severity of retinopa-
thy (P  0.02). Half of the subjects with
moderate retinopathy and all with severe
and proliferative retinopathy had PSN
(online appendix Table A2).
Men with PSN had higher systolic
blood pressure (152  18 vs. 144  17
mmHg;P0.04).SubjectswithPSNhad
more vascular disease as judged by a two-
fold increase of pathological electrocar-
diograms (31 vs. 15%; P  0.04). They
also had greater incidence of PVD (41 vs.
17%; P  0.002), and a history of foot
ulceration was more common in connec-
tion with PSN (14 vs. 2%; P  0.008)
(Table 1).
Subjects with PSN had lower HDL
cholesterol (1.15  0.37 vs. 1.26  0.38
mmol/l; P  0.0.07) but comparable
A1C. They also had comparable IGF-1
(PSN12056g/lvs.noPSN13765
g/l; P  0.1) but higher IGFBP-1 (33 
30 vs. 20  17 g/l; P  0.005), a lower
IGF-1–to–IGFBP-1 ratio (10.3  16.5
vs. 12.6  11.7; P  0.002), and lower
IGFBP-3 (3,168  1,113 vs. 3,678 
1,044 g/l; P  0.008).
Insensitivity to touch as judged by
monoﬁlament testing affected 15%. Sub-
jects with a pathological monoﬁlament
had a two- to threefold increase in preva-
lence of PVD (57 vs. 20%; P  0.0007)
and overt nephropathy (24 vs. 7%; P 
0.03). Also, incidence of foot ulcers was
strongly associated with a pathological
monoﬁlament (pathological monoﬁla-
ment 33% vs. nonpathological 2%; P 
0.00002). Prevalence of pathological
monoﬁlaments increased with the sever-
ityofnephropathy(nonephropathy11%,
incipient nephropathy 24%, and overt
nephropathy 38%; P  0.02).
In summary, PSN in the study popu-
lation affected men more often than
women and was univariately associated
with age, diabetes duration, retinopathy,
nephropathy, PVD, HDL cholesterol, and
abnormalities in IGF-1 and its binding
proteins but not with A1C.
Retinopathy, univariate correlations
The prevalence of diabetes retinopathy at
review of retinal examinations was 29%.
Eleven percent had mild retinopathy,
13%moderate,2%severe,and2%prolif-
erative (Table 1 and online appendix Ta-
bleA1).Subjectswithretinopathywereof
thesameageasthosewithout(62.06.9
vs. 61.6  7.5 years, respectively; P 
0.9) but had a longer diabetes duration
(10.0  7.0 vs. 5.9  4.9 years; P 
0.001), worse glucose control as judged
by A1C (6.8  1.2 vs. 6.3  1.2%; P 
0.02), and higher urinary albumin
(244  554 vs. 22  48 mg/l; P  0.03).
Blood pressure was comparable in sub-
jects with and without retinopathy,
Table 1—Relations between prevalence of diabetic complications
PSN Retinopathy Overt nephropathy
 P  P  P
Cardiovascular disease 57/95 (60) 33/49 (67) NS 54/94 (57) 26/38 (68) NS 84/140 (60) 10/13 (77) NS
Pathological electrocardiogram 12/81 (15) 14/45 (31) 0.04 17/82 (21) 9/32 (28) NS 22/118 (19) 4/12 (33) NS
Cerebrovascular lesion 10/95 (11) 5/49 (10) NS 10/94 (11) 4/38 (11) NS 14/140 (10) 3/13 (23) NS
PVD 16/95 (17) 20/49 (41) 0.002 26/94 (28) 11/38 (29) NS 36/140 (26) 4/13 (31) NS
Foot ulcer 2/95 (2) 7/49 (14) 0.008 7/94 (7) 4/38 (11) NS 9/140 (6) 2/13 (15) NS
PSN — — — 27/85 (32) 16/35 (46) 0.1 41/128 (32) 8/13 (62) 0.06
Retinopathy 19/77 (25) 16/43 (37) 0.1 — — — 31/120 (26) 7/10 (70) 0.007
Overt nephropathy 5/92 (5) 8/49 (16) 0.06 3/92 (3) 7/38 (18) 0.007 — — —
Data are frequencies (%) unless otherwise indicated. P refers to Fisher’s exact two-tailed test values. PSN is deﬁned as pathological ﬁlament or VPT 25 V.
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ciated with a higher resting pulse (74 
12 vs. 66  9 bpm; P  0.02).
A VPT 25 V was more common in
subjects with retinopathy (45 vs. 27%;
P  0.08) as were higher VPTs in general
(25.68.9vs.20.58.9V;P0.007).
Also, prevalence of PSN increased with
the level of retinopathy, as stated above.
Overt nephropathy was more common in
subjectswithretinopathy(18vs.3%;P
0.007), and severity of nephropathy in-
creased with severity of retinopathy (P 
0.00001) (online appendix Table A2). In
summary, retinopathy was univariately
associated with diabetes duration, glu-
cose control, nephropathy, and periph-
eral neuropathy.
Nephropathy, univariate
correlations
At examination, incipient nephropathy
affected 14% and overt nephropathy 8%.
Of subjects with overt nephropathy, 85%
were male (n  11). Subjects with overt
nephropathy had a twofold increase of
PSN (62 vs. 32%; P  0.06) and higher
VPTs (28.4  12.6 vs. 20.9  9.0 V; P 
0.02). Insensitivity to touch as assessed
with monoﬁlament testing was more
common in overt nephropathy (24 vs.
7%; P  0.03) and also increased in prev-
alence with severity of nephropathy (no
nephropathy 11%, incipient nephropa-
thy 24%, and overt nephropathy 38%;
P  0.02).
Retinopathy was three times as com-
mon in subjects with overt nephropathy as
in those without (70 vs. 26%; P  0.007),
and severity of retinopathy increased with
level of nephropathy (P  0.0001) (online
appendixTableA3).Insummary,nephrop-
athy was univariately closely linked to neu-
ropathy and retinopathy.
PSN and retinopathy, univariate
correlations
In subjects without retinopathy, PSN af-
fected men more and was associated with
higher age, higher creatinine, higher uri-
nary albumin, and higher cystatin C,
whereas diabetes duration and glucose
control were comparable between sub-
jects with retinopathy and without, as
shown in Table 2 and online appendix
Table A4. They also had lower BMI
(27.9  4.1 vs. 30.3  4.9 kg/m
2; P 
0.03), higher IGFBP-1 (34  34 vs. 18 
15 g/l; P  0.04), lower IGFBP-3
(3,190862vs.3,6701,039g/l;P
0.04), and a higher IGF-1–to–IGFBP-1
ratio (13.0  20.8 vs. 12.5  11.2; P 
0.04).
PSN in subjects with no retinopathy
was associated with a nearly threefold in-
crease of pathological electrocardiograms
(36 vs. 13%; P  0.03) and PVD (52 vs.
16%; P  0.001) and a sixfold increase of
foot ulcers (19 vs. 3%).
Subjects with PSN but without reti-
nopathy were comparable in age with
those with both PSN and retinopathy but
possibly had shorter diabetes durations
(7.15.9vs.10.87.1years;P0.07)
and better glucose control (6.2  1.2 vs.
6.9  1.0 mmol/l; P  0.07), whereas
cystatin C was also comparable. VPTs
were lower in subjects with PSN alone
than in those with both PSN and retinop-
athy (30.2  7 vs. 35.0  7.88 V; P 
0.05).
PVDwastwiceascommoninsubjects
with only PSN as in those with PSN and
retinopathy (52 vs. 19%; P  0.05),
whereas overt nephropathy was possibly
less common in the absence of retinopa-
thy (7 vs. 31%; P  0.08).
Table 2—Clinical characteristics and fasting metabolic proﬁle in subjects with or without retinopathy in association with presence of PSN,
deﬁned as pathological monoﬁlament or VPT >25 V
No retinopathy Retinopathy
P* P†s PSN PSN P PSN PSN P
n 58 27 19 16
% male 48 81 0.004 58 69 NS NS NS
Age (years) 59.1  7.6 65.3  5.3 0.0001 60.5  8.1 63.8  5.6 NS 0.03 NS
Diabetes duration (years) 5.3  4.3 7.1  5.9 NS 8.8  6.1 10.8  7.1 NS 0.001 0.07
BMI (kg/m
2)
) 30.3  4.9 27.9  4.1 0.03 29.5  4.7 29.8  5.0 NS NS NS
Waist index 1.16  0.14 1.11  0.12 0.1 1.13  0.16 1.15  0.14 NS NS NS
hsCRP (mg/l) 2.60  2.45 3.38  4.02 NS 3.08  2.46 2.55  2.08 NS NS NS
Systolic blood pressure (mmHg) 145  18 150  17 NS 149  21 154  20 NS NS NS
Diastolic blood pressure (mmHg) 84  98 3  10 NS 79  88 7  13 0.07 NS NS
Fasting plasma glucose (mmol/l) 8.8  2.8 8.9  3.8 NS 8.5  2.4 10.2  2.4 0.05 0.05 0.1
A1C (%) 6.3  1.3 6.2  1.2 NS 6.7  1.3 6.9  1.0 NS 0.06 0.07
IGF-1 (g/l) 130  64 116  55 NS 133  59 138  63 NS NS NS
IGF-1 SD 0.92  1.71 1.03  2.13 NS 0.58  1.62 0.35  1.62 NS NS NS
IGFBP-1 (g/l) 18  15 34  34 0.04 19  18 29  18 0.02 0.004 NS
IGFBP-3 (g/l) 3,670  1,039 3,190  861 0.04 3,724  1,253 3,314  1,518 NS NS NS
IGF-1–to–IGFBP-1 ratio 12.5  11.2 13.0  20.8 0.04 13.2  12.3 6.4  5.3 0.03 0.05 NS
Cholesterol (mmol/l) 5.04  1.01 5.13  1.40 NS 4.93  1.26 4.80  0.86 NS NS NS
HDL cholesterol (mmol/l) 1.23  0.35 1.15  0.36 NS 1.23  0.35 1.16  0.44 NS NS NS
Triglycerides (mmol/l) 1.85  1.18 2.05  1.92 NS 1.57  0.68 1.87  1.33 NS NS NS
Cystatin C (mg/l) 0.68  0.23 0.88  0.42 0.07 0.80  0.24 0.87  0.31 NS 0.05 NS
Creatinine (mol/l) 74  15 86  22 0.004 73  16 77  23 NS NS 0.1
UAlb (mg/l) 11  11 36  67 0.06 102  251 463  789 NS 0.004 0.1
VPT (V) 16.1  5.1 30.2  7.8 — 17.8  3.3 35.0  7.8 — — 0.05
Data are means  SD unless otherwise indicated. P refers to one-way ANOVA. IGF-1 SD is the score as calculated from healthy subjects. *No retinopathy/PSN vs.
retinopathy/PSN. †No retinopathy/PSN vs. retinopathy/PSN.
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retinopathy was univariately associated
with age, sex, PVD, kidney function,
macrovascular disease as judged by
electrocardiogram and IGFBPs but not
with glucose control or diabetes dura-
tion. VPT was lower in subjects with
PSN alone than in those with PSN com-
bined with retinopathy.
Multivariate analysis
Retinopathy was independently associ-
ated with diabetes duration (odds ratio
[OR] 1.10; P  0.01) and glucose control
as judged by A1C (1.38; P  0.06), and
overt nephropathy increased the risk of
retinopathytwofold(2.04;P0.09)(on-
line appendix Table A5). Peripheral sen-
sory neuropathy was associated with sex,
with men more affected (2.01, P  0.02)
andincreasedwithage(1.12;P0.008),
whereas diabetes duration lost signiﬁ-
cance(P0.1).PresenceofPVDdoubled
the risk of PSN (2.31; P  0.007),
whereas an increase of HDL cholesterol
diminished the risk (0.21; P  0.05).
Also, a high IGFBP-1 was connected to
increased risk of PSN (1.03; P  0.05)
(Table 3).
When tobacco use was included in
themodelandsubjectswithalcoholover-
consumption were excluded, PSN was
still associated with sex (OR 2.00; P 
0.07) and PVD (2.70; P  0.03), whereas
use of tobacco turned out to be insigniﬁ-
cant.However,theinteractionofmalesex
and tobacco use possibly increased the
probability of PSN (1.94; P  0.08) (on-
line appendix Table A6). In summary,
PSN was independently associated with
sex, aging, PVD, HDL cholesterol, and
possibly IGFBP-1.
CONCLUSIONS — In this represen-
tativepopulation-basedstudy,whichalso
assessed the status of nonparticipants, we
conﬁrm and extend associations between
PSN and other microvascular complica-
tions in type 2 diabetes, in particular,
retinopathy. Importantly, we demon-
strate a close association of PSN and
PVD that seems independent of glucose
control. Furthermore, we report an as-
sociation between the IGF-IGFBP axis
and neuropathy.
We ﬁnd that PSN was more common
in our study population (34%) than reti-
nopathy (29%) and nephropathy (22%).
PSN affected men more often than
women and was related to height, age,
and diabetes duration. These ﬁndings
conﬁrmpreviousreports(3,10,11).How-
ever, we did not ﬁnd association with the
levelofglucosecontrolasmeasuredatthe
time of the investigation. The latter ﬁnd-
ingisincontrasttosomepreviousreports
(12–14). However, in agreement with
earlier reports, we found an association
betweenPSNandretinopathy,suggesting
impaired metabolic control as a cause.
Comparing subjects with only PSN and
subjects with both PSN and retinopathy,
we found that subjects with PSN alone
had shorter diabetes durations and better
glucose control but also had PVD signiﬁ-
cantly more often than subjects with both
PSN and retinopathy. A ﬁnding of a close
relationship between PSN and PVD has
previously been reported (15). Our inter-
pretation of this is that PVD causes rela-
tive hypoxemia and so is another risk
factor for PSN that, in turn, may be fur-
ther enhanced by the presence of hyper-
glycemia, which in itself is a sufﬁcient
cause of PSN.
HDL cholesterol was in this study
lowerinsubjectswithPSN(P0.07)and
in multivariate regression analysis was in-
dependently associated with PSN (P 
0.05).DecreasedHDLcholesterolisarisk
factor for PVD in type 2 diabetes (16) and
also for PSN in the metabolic syndrome
(17). Most of the proposed pathogenetic
metabolic factors for PSN also have vas-
cular effects (18).
OursubjectswithPSNhadhigherIG-
FBP-1, as previously demonstrated in
type 1 diabetes, (19), a lower IGF-1–to–
IGFBP-1 ratio, and lower IGFBP-3 than
subjects without PSN, suggesting lower
bioactive IGF-1. Autocrine and paracrine
IGF-1ispostulatedtobecrucialformain-
tained nerve function, and the natural de-
cline in IGFs with age could be a factor
behind the age-dependent increase of
PSN(4,20).IGFBP-1isbelievedtodown-
regulate IGF action; hence, an increase of
IGFBP-1 resulting in a lower IGF-1–to–
IGFBP-1ratiosuggestsreducedIGFactiv-
ity, which, in turn, could predispose for
PSN. The higher IGFBP-1, which is regu-
lated by insulin, suggests insulin deﬁ-
ciency in the liver because there was no
correlation between IGFBP-1 and hsCRP
(21).
Retinopathy was, as expected, associ-
ated with diabetes duration, hyperglyce-
mia, PSN, and nephropathy (14,22–24).
Further, we report that women with reti-
nopathy have higher resting pulses than
women without retinopathy—this ﬁnd-
ing could suggest a connection between
retinopathy and autonomic neuropathy,
as reported in a pupillometry study (25).
As to dyslipidemia, which has been re-
ported as a risk factor (23), we found no
association.
Logistic regression models conﬁrmed
to a large extent the ﬁndings in univariate
analysis. Hence, there was an association
of risk for PSN with age (12% per year),
IGFBP-1 (3% per g/l), HDL cholesterol
(80% per mmol/l), male sex (200%
greater risk), and PVD (230% greater
risk).Furthermore,retinopathywasinde-
pendently associated with diabetes dura-
tionandA1C,whereasovertnephropathy
was independently associated with age
and retinopathy. Hence, a previously
known connection between retinopathy
and nephropathy was conﬁrmed.
In conclusion, we report PSN to be
independently associated with PVD and
HDL cholesterol in addition to the well-
known associations of PSN with age and
sex. This means that patients with PSN
but without retinopathy should be sus-
pected to have PVD. Further, we report
for the ﬁrst time, to our knowledge, an
association between PSN and IGFBP-1 in
type 2 diabetes.
The ﬁndings in this study are subject
to the limitations of a cross-sectional
Table 3—Binomial logit–modeled probability for PSN in the study population
Level of effect OR Estimate P
Age (years) 1.12 (1.03–1.21) 0.11 0.008
Diabetes duration (years) 1.08 (0.98–1.19) 0.08 0.1
IGFBP-1 (g/l) 1.03 (1.00–1.05) 0.03 0.05
Urinary albumin (mg/l) 1.00 (1.00–1.01) 0.00 0.2
HDL cholesterol (mmol/l) 0.21 (0.04–0.98) 1.57 0.05
Sex Male 2.01 (1.10–3.67) 0.70 0.02
PVD PVD 2.31 (1.25–4.25) 0.84 0.007
Sex*PVD 1 1.60 (0.88–2.91) 0.47 0.1
Data are OR (95% CI) unless otherwise indicated.
Ka ¨rvestedt and Associates
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prospective study of this cohort.
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